Screener
4D Molecular Therapeutics FDMT Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (73,620) | (53,621) |
| Other income (expense): | ||
| Interest income | 4,864 | 5,582 |
| Other income (expense), net | (4) | 67 |
| Total other income, net | 4,860 | 5,649 |
| Net loss | $(68,760) | $(47,972) |
| Net loss per share, basic and diluted | $(1.01) | $(0.86) |
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 68,064,586 | 55,744,047 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's other income (expense)?
- 4D Molecular Therapeutics (FDMT) reported other income (expense) of $4.86M in Q1 2026.
- How has 4D Molecular Therapeutics's other income (expense) changed year-over-year?
- 4D Molecular Therapeutics's other income (expense) decreased by 14.0% year-over-year, from $5.65M to $4.86M.
- What is the long-term trend for 4D Molecular Therapeutics's other income (expense)?
- Over 3 years (2022 to 2025), 4D Molecular Therapeutics's other income (expense) has grown at a 97.1% compound annual growth rate (CAGR), from $2.54M to $19.44M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about 4D Molecular Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude